Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Cytochrome P-450 CYP3A"" wg kryterium: Temat


Tytuł :
Quantitative evaluation of hepatic and intestinal induction of CYP3A in clinical practice.
Autorzy :
Tsutsui H; Research division, Chugai Pharmaceutical Co., Ltd, Gotemba, Shizuoka, Japan.
Kato M; Research division, Chugai Pharmaceutical Co., Ltd, Gotemba, Shizuoka, Japan.
Kuramoto S; Research division, Chugai Pharmaceutical Co., Ltd, Gotemba, Shizuoka, Japan.
Sekiguchi N; Research division, Chugai Pharmaceutical Co., Ltd, Gotemba, Shizuoka, Japan.
Shindoh H; Research division, Chugai Pharmaceutical Co., Ltd, Gotemba, Shizuoka, Japan.
Ozeki K; Research division, Chugai Pharmaceutical Co., Ltd, Gotemba, Shizuoka, Japan.
Pokaż więcej
Źródło :
Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2020 Aug; Vol. 50 (8), pp. 875-884. Date of Electronic Publication: 2020 Jan 07.
Typ publikacji :
Journal Article
MeSH Terms :
Cytochrome P-450 CYP3A/*metabolism
Intestines/*physiology
Liver/*metabolism
Alfentanil ; Area Under Curve ; Cytochrome P-450 CYP3A Inducers
Czasopismo naukowe
Tytuł :
Association between clinically relevant toxicities of pazopanib and sunitinib and the use of weak CYP3A4 and P-gp inhibitors.
Autorzy :
Azam C; Pharmacy department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Claraz P; Pharmacy department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Chevreau C; Oncology department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Vinson C; Pharmacy department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Cottura E; Oncology department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Mourey L; Oncology department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Pouessel D; Oncology department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Guibaud S; Oncology department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Pollet O; Oncology department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Le Goff M; Oncology department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Bardies C; Oncology department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Pelagatti V; Pharmacy department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France.
Canonge JM; Pharmacy department IUCT (Institut Universitaire du Cancer) Oncopole, Centre Hospitalier Universitaire, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, France.
Puisset F; Pharmacy department IUCT (Institut Universitaire du Cancer) Oncopole, Institut Claudius Regaud, 1 avenue Irène Joliot-Curie, Toulouse CEDEX 9, 31059, France. .; Centre de Recherches en Cancérologie de Toulouse (CRCT), Team 14, INSERM UMR1037, Université de Toulouse, 2 avenue Hubert Curien, CS53717, Toulouse CEDEX 1, France. .
Pokaż więcej
Źródło :
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2020 Apr; Vol. 76 (4), pp. 579-587. Date of Electronic Publication: 2020 Jan 13.
Typ publikacji :
Journal Article
MeSH Terms :
ATP Binding Cassette Transporter, Subfamily B, Member 1/*antagonists & inhibitors
Cytochrome P-450 CYP3A Inhibitors/*toxicity
Pyrimidines/*toxicity
Sulfonamides/*toxicity
Sunitinib/*toxicity
Aged ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inhibitors/administration & dosage ; Cytochrome P-450 CYP3A Inhibitors/pharmacokinetics ; Dose-Response Relationship, Drug ; Drug Interactions ; Female ; Humans ; Male ; Pyrimidines/administration & dosage ; Pyrimidines/pharmacokinetics ; Retrospective Studies ; Sulfonamides/administration & dosage ; Sulfonamides/pharmacokinetics ; Sunitinib/administration & dosage ; Sunitinib/pharmacokinetics
Czasopismo naukowe
Tytuł :
Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects.
Autorzy :
Mu S; Clinical Pharmacology, BeiGene USA, 2955 Campus Drive, Suite 300, San Mateo, CA, 94403, USA.
Tang Z; Clinical Pharmacology, BeiGene USA, 2955 Campus Drive, Suite 300, San Mateo, CA, 94403, USA.
Novotny W; Clinical Development, BeiGene USA, San Mateo, CA, USA.
Tawashi M; Clinical Operations, BeiGene USA, San Mateo, CA, USA.
Li TK; Drug Safety and Pharmacovigilance, BeiGene USA, San Mateo, CA, USA.
Ou Y; Clinical Pharmacology, BeiGene USA, 2955 Campus Drive, Suite 300, San Mateo, CA, 94403, USA.
Sahasranaman S; Clinical Pharmacology, BeiGene USA, 2955 Campus Drive, Suite 300, San Mateo, CA, 94403, USA. .
Pokaż więcej
Źródło :
Cancer chemotherapy and pharmacology [Cancer Chemother Pharmacol] 2020 Feb; Vol. 85 (2), pp. 391-399. Date of Electronic Publication: 2019 Dec 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cytochrome P-450 CYP3A Inducers/*therapeutic use
Cytochrome P-450 CYP3A Inhibitors/*therapeutic use
Itraconazole/*therapeutic use
Piperidines/*pharmacokinetics
Protein Kinase Inhibitors/*pharmacokinetics
Pyrazoles/*pharmacokinetics
Pyrimidines/*pharmacokinetics
Rifampin/*therapeutic use
Adolescent ; Adult ; Aged ; Area Under Curve ; Cytochrome P-450 CYP3A/metabolism ; Drug Interactions/physiology ; Female ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Young Adult
Czasopismo naukowe
Tytuł :
Synthesis of Spin-Labelled Bergamottin: A Potent CYP3A4 Inhibitor with Antiproliferative Activity.
Autorzy :
Zsidó BZ; Department of Pharmacology and Pharmacotherapy, University of Pécs, Medical School, Szigeti út 12, H-7624 Pécs, Hungary.
Balog M; Institute of Organic and Medicinal Chemistry, University of Pécs, Medical School, Honvéd utca 1, H-7624 Pécs, Hungary.
Erős N; Institute of Organic and Medicinal Chemistry, University of Pécs, Medical School, Honvéd utca 1, H-7624 Pécs, Hungary.
Poór M; Department of Pharmacology, University of Pécs, Faculty of Pharmacy, Szigeti út 12, H-7624 Pécs, Hungary.; János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary.
Mohos V; Department of Pharmacology, University of Pécs, Faculty of Pharmacy, Szigeti út 12, H-7624 Pécs, Hungary.; János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary.
Fliszár-Nyúl E; Department of Pharmacology, University of Pécs, Faculty of Pharmacy, Szigeti út 12, H-7624 Pécs, Hungary.; János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary.
Hetényi C; Department of Pharmacology and Pharmacotherapy, University of Pécs, Medical School, Szigeti út 12, H-7624 Pécs, Hungary.
Nagane M; Department of Biochemistry, School of Veterinary Medicine, Azabu University, 1-17-71 Fuchinobe, Chuo-ku, Sagamihara, Kanagawa 252-5201, Japan.
Hideg K; Institute of Organic and Medicinal Chemistry, University of Pécs, Medical School, Honvéd utca 1, H-7624 Pécs, Hungary.
Kálai T; Institute of Organic and Medicinal Chemistry, University of Pécs, Medical School, Honvéd utca 1, H-7624 Pécs, Hungary.; János Szentágothai Research Center, University of Pécs, Ifjúság útja 20, H-7624 Pécs, Hungary.
Bognár B; Institute of Organic and Medicinal Chemistry, University of Pécs, Medical School, Honvéd utca 1, H-7624 Pécs, Hungary.
Pokaż więcej
Źródło :
International journal of molecular sciences [Int J Mol Sci] 2020 Jan 13; Vol. 21 (2). Date of Electronic Publication: 2020 Jan 13.
Typ publikacji :
Journal Article
MeSH Terms :
Cytochrome P-450 CYP3A Inhibitors*/chemical synthesis
Cytochrome P-450 CYP3A Inhibitors*/chemistry
Cytochrome P-450 CYP3A Inhibitors*/pharmacology
Furocoumarins*/chemistry
Furocoumarins*/pharmacology
Cell Proliferation/*drug effects
Cytochrome P-450 CYP3A/*metabolism
Spin Labels/*chemical synthesis
Animals ; HeLa Cells ; Humans ; Mice ; NIH 3T3 Cells
Czasopismo naukowe
Tytuł :
Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect.
Autorzy :
Stader F; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Khoo S; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Stoeckle M; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Back D; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Hirsch HH; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.; Transplantation & Clinical Virology, Department of Biomedicine, University of Basel, Basel, Switzerland.
Battegay M; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.; University of Basel, Basel, Switzerland.
Marzolini C; Division of Infectious Diseases and Hospital Epidemiology, Departments of Medicine and Clinical Research, University Hospital Basel, Basel, Switzerland.; Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Pokaż więcej
Źródło :
The Journal of antimicrobial chemotherapy [J Antimicrob Chemother] 2020 Oct 01; Vol. 75 (10), pp. 3084-3086.
Typ publikacji :
Letter; Research Support, Non-U.S. Gov't
MeSH Terms :
Betacoronavirus*
Coronavirus Infections/*metabolism
Cytochrome P-450 CYP3A Inhibitors/*metabolism
Drug Interactions/*physiology
Lopinavir/*metabolism
Pneumonia, Viral/*metabolism
Ritonavir/*metabolism
Adult ; Aged ; Aged, 80 and over ; Coronavirus Infections/drug therapy ; Cytochrome P-450 CYP3A Inhibitors/administration & dosage ; Drug Therapy, Combination ; Female ; Humans ; Lopinavir/administration & dosage ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/drug therapy ; Ritonavir/administration & dosage ; Time Factors ; Withholding Treatment/trends ; Young Adult
SCR Disease Name :
COVID-19
Raport
Tytuł :
CYPs-mediated drug-drug interactions on psoralidin, isobavachalcone, neobavaisoflavone and daidzein in rats liver microsomes.
Autorzy :
Shi M; National R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng, 475004, China.
Cui Y; National R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng, 475004, China.
Liu C; National R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng, 475004, China; Joint International Research Laboratory of Food & Medicine, Henan Province, Henan University, Kaifeng, 475004, China.
Li C; National R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng, 475004, China; Kaifeng Key Laboratory of Functional Components in Health Food, Kaifeng, 475004, Henan, China.
Liu Z; National R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng, 475004, China. Electronic address: .
Kang WY; National R & D Center for Edible Fungus Processing Technology, Henan University, Kaifeng, 475004, China; Joint International Research Laboratory of Food & Medicine, Henan Province, Henan University, Kaifeng, 475004, China. Electronic address: .
Pokaż więcej
Źródło :
Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association [Food Chem Toxicol] 2020 Feb; Vol. 136, pp. 111027. Date of Electronic Publication: 2019 Dec 21.
Typ publikacji :
Journal Article
MeSH Terms :
Benzofurans/*toxicity
Chalcones/*toxicity
Coumarins/*toxicity
Cytochrome P-450 CYP2E1/*metabolism
Cytochrome P-450 CYP3A/*metabolism
Isoflavones/*toxicity
Microsomes, Liver/*metabolism
Animals ; Benzofurans/metabolism ; Chalcones/metabolism ; Coumarins/metabolism ; Cytochrome P-450 CYP2E1 Inhibitors/metabolism ; Cytochrome P-450 CYP2E1 Inhibitors/toxicity ; Cytochrome P-450 CYP3A Inhibitors/metabolism ; Cytochrome P-450 CYP3A Inhibitors/toxicity ; Drug Interactions ; Isoflavones/metabolism ; Rats, Sprague-Dawley
Czasopismo naukowe
Tytuł :
In vitro interactions of abiraterone, erythromycin, and CYP3A4: implications for drug-drug interactions.
Autorzy :
Masamrekh RA; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow, 119121, Russia.; Pirogov Russian National Research Medical University, Ostrovityanova Street, 1, Moscow, 117997, Russia.
Kuzikov AV; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow, 119121, Russia.; Pirogov Russian National Research Medical University, Ostrovityanova Street, 1, Moscow, 117997, Russia.
Haurychenka YI; Pirogov Russian National Research Medical University, Ostrovityanova Street, 1, Moscow, 117997, Russia.
Shcherbakov KA; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow, 119121, Russia.
Veselovsky AV; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow, 119121, Russia.
Filimonov DA; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow, 119121, Russia.
Dmitriev AV; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow, 119121, Russia.
Zavialova MG; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow, 119121, Russia.
Gilep AA; Institute of Bioorganic Chemistry NASB, 5 Academician V.F. Kuprevich Street, Build 2, Minsk, BY-220141, Belarus.
Shkel TV; Institute of Bioorganic Chemistry NASB, 5 Academician V.F. Kuprevich Street, Build 2, Minsk, BY-220141, Belarus.
Strushkevich NV; Institute of Bioorganic Chemistry NASB, 5 Academician V.F. Kuprevich Street, Build 2, Minsk, BY-220141, Belarus.
Usanov SA; Institute of Bioorganic Chemistry NASB, 5 Academician V.F. Kuprevich Street, Build 2, Minsk, BY-220141, Belarus.
Archakov AI; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow, 119121, Russia.; Pirogov Russian National Research Medical University, Ostrovityanova Street, 1, Moscow, 117997, Russia.
Shumyantseva VV; Institute of Biomedical Chemistry, Pogodinskaya Street, 10, Build 8, Moscow, 119121, Russia.; Pirogov Russian National Research Medical University, Ostrovityanova Street, 1, Moscow, 117997, Russia.
Pokaż więcej
Źródło :
Fundamental & clinical pharmacology [Fundam Clin Pharmacol] 2020 Feb; Vol. 34 (1), pp. 120-130. Date of Electronic Publication: 2019 Aug 05.
Typ publikacji :
Journal Article
MeSH Terms :
Androstenes/*pharmacology
Anti-Bacterial Agents/*pharmacokinetics
Cytochrome P-450 CYP3A/*drug effects
Erythromycin/*pharmacokinetics
Antineoplastic Agents/pharmacology ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Drug Interactions ; Humans ; Hydroxylation ; Molecular Docking Simulation
Czasopismo naukowe
Tytuł :
In vitro Inhibitory Effects of Isofraxidin on Human Liver Cytochrome P450 Enzymes.
Autorzy :
Song X; Department of Pharmacy, Yidu Central Hospital of Weifang, Weifang, China.
Dong G; Department of Pharmacy, Yidu Central Hospital of Weifang, Weifang, China.
Zhou Y; Department of Pharmacy, Yidu Central Hospital of Weifang, Weifang, China, .
Pokaż więcej
Źródło :
Pharmacology [Pharmacology] 2019; Vol. 103 (3-4), pp. 120-127. Date of Electronic Publication: 2018 Dec 13.
Typ publikacji :
Journal Article
MeSH Terms :
Cytochrome P-450 CYP2E1*/metabolism
Cytochrome P-450 CYP3A*/metabolism
Coumarins/*pharmacology
Cytochrome P-450 CYP1A1/*antagonists & inhibitors
Cytochrome P-450 Enzyme Inhibitors/*pharmacology
Liver/*drug effects
Coumarins/toxicity ; Cytochrome P-450 CYP1A1/metabolism ; Cytochrome P-450 CYP2E1 Inhibitors/pharmacology ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Cytochrome P-450 Enzyme Inhibitors/toxicity ; Drug Interactions ; Humans ; Kinetics ; Liver/enzymology ; Microsomes, Liver/drug effects ; Microsomes, Liver/enzymology
Czasopismo naukowe
Tytuł :
Metabolism of Benzalkonium Chlorides by Human Hepatic Cytochromes P450.
Autorzy :
Seguin RP; Department of Medicinal Chemistry, School of Pharmacy , University of Washington , Seattle , Washington 98195 , United States.
Herron JM; Department of Environmental and Occupational Health Sciences, School of Public Health , University of Washington , Seattle , Washington 98195 , United States.
Lopez VA; Department of Medicinal Chemistry, School of Pharmacy , University of Washington , Seattle , Washington 98195 , United States.
Dempsey JL; Department of Environmental and Occupational Health Sciences, School of Public Health , University of Washington , Seattle , Washington 98195 , United States.
Xu L; Department of Medicinal Chemistry, School of Pharmacy , University of Washington , Seattle , Washington 98195 , United States.; Department of Environmental and Occupational Health Sciences, School of Public Health , University of Washington , Seattle , Washington 98195 , United States.
Pokaż więcej
Źródło :
Chemical research in toxicology [Chem Res Toxicol] 2019 Dec 16; Vol. 32 (12), pp. 2466-2478. Date of Electronic Publication: 2019 Dec 03.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms :
Aryl Hydrocarbon Hydroxylases/*metabolism
Benzalkonium Compounds/*metabolism
Cytochrome P-450 CYP2D6/*metabolism
Cytochrome P-450 CYP3A/*metabolism
Disinfectants/*metabolism
Amidines/pharmacology ; Animals ; Aryl Hydrocarbon Hydroxylases/chemistry ; Benzalkonium Compounds/chemistry ; Carbon Isotopes/chemistry ; Cytochrome P-450 CYP2D6/chemistry ; Cytochrome P-450 CYP2D6 Inhibitors/pharmacology ; Cytochrome P-450 CYP3A/chemistry ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Female ; Humans ; Hydroxylation/drug effects ; Kinetics ; Male ; Mice ; Microsomes, Liver/metabolism ; Oxidation-Reduction ; Quinidine/pharmacology
Czasopismo naukowe
Tytuł :
Prolonged-Release Tacrolimus Is Less Susceptible to Interaction With the Strong CYP3A Inhibitor Voriconazole in Healthy Volunteers.
Autorzy :
Huppertz A; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.
Ott C; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.
Bruckner T; Department of Medical Biometry and Informatics, University of Heidelberg, Heidelberg, Germany.
Foerster KI; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.
Burhenne J; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.
Weiss J; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.
Zorn M; Central Laboratory, University Hospital Heidelberg, Heidelberg, Germany.
Haefeli WE; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.
Czock D; Department of Clinical Pharmacology and Pharmacoepidemiology, University of Heidelberg, Heidelberg, Germany.
Pokaż więcej
Źródło :
Clinical pharmacology and therapeutics [Clin Pharmacol Ther] 2019 Dec; Vol. 106 (6), pp. 1290-1298. Date of Electronic Publication: 2019 Jul 10.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cytochrome P-450 CYP3A Inhibitors/*pharmacokinetics
Tacrolimus/*pharmacokinetics
Voriconazole/*pharmacokinetics
Adult ; Area Under Curve ; Cytochrome P-450 CYP3A/genetics ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inhibitors/adverse effects ; Delayed-Action Preparations ; Drug Interactions ; Healthy Volunteers ; Humans ; Male ; Middle Aged ; Tacrolimus/administration & dosage ; Tacrolimus/adverse effects ; Voriconazole/adverse effects ; Young Adult
Czasopismo naukowe
Tytuł :
Siponimod pharmacokinetics, safety, and tolerability in combination with the potent CYP3A4 inhibitor itraconazole in healthy subjects with different CYP2C9 genotypes.
Autorzy :
Gardin A; Novartis Institutes for Biomedical Research, Basel, Switzerland. .
Shakeri-Nejad K; Novartis Institutes for Biomedical Research, Basel, Switzerland.
Feller A; Novartis Institutes for Biomedical Research, Basel, Switzerland.
Huth F; Novartis Institutes for Biomedical Research, Basel, Switzerland.
Neelakantham S; Novartis Healthcare Pvt. Ltd., Hyderabad, India.
Dumitras S; Novartis Institutes for Biomedical Research, Basel, Switzerland.
Pokaż więcej
Źródło :
European journal of clinical pharmacology [Eur J Clin Pharmacol] 2019 Nov; Vol. 75 (11), pp. 1565-1574. Date of Electronic Publication: 2019 Aug 07.
Typ publikacji :
Clinical Trial; Journal Article
MeSH Terms :
Cytochrome P-450 CYP3A*
Azetidines/*pharmacokinetics
Benzyl Compounds/*pharmacokinetics
Cytochrome P-450 CYP2C9/*genetics
Cytochrome P-450 CYP3A Inhibitors/*pharmacology
Itraconazole/*pharmacology
Sphingosine 1 Phosphate Receptor Modulators/*pharmacokinetics
Adolescent ; Adult ; Area Under Curve ; Azetidines/adverse effects ; Azetidines/blood ; Benzyl Compounds/adverse effects ; Benzyl Compounds/blood ; Drug Interactions ; Electrocardiography/drug effects ; Female ; Genotype ; Healthy Volunteers ; Humans ; Lymphocyte Count ; Male ; Middle Aged ; Sphingosine 1 Phosphate Receptor Modulators/adverse effects ; Sphingosine 1 Phosphate Receptor Modulators/blood ; Young Adult
Czasopismo naukowe
Tytuł :
Interindividual Variation in CYP3A Activity Influences Lapatinib Bioactivation.
Autorzy :
Bissada JE; Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, Nashville, Tennessee (J.E.B., V.T., A.A.A., K.J.W., R.D.C., K.D.J.); Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee (R.D.C., K.D.J.); and Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (K.D.J.).
Truong V; Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, Nashville, Tennessee (J.E.B., V.T., A.A.A., K.J.W., R.D.C., K.D.J.); Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee (R.D.C., K.D.J.); and Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (K.D.J.).
Abouda AA; Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, Nashville, Tennessee (J.E.B., V.T., A.A.A., K.J.W., R.D.C., K.D.J.); Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee (R.D.C., K.D.J.); and Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (K.D.J.).
Wines KJ; Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, Nashville, Tennessee (J.E.B., V.T., A.A.A., K.J.W., R.D.C., K.D.J.); Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee (R.D.C., K.D.J.); and Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (K.D.J.).
Crouch RD; Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, Nashville, Tennessee (J.E.B., V.T., A.A.A., K.J.W., R.D.C., K.D.J.); Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee (R.D.C., K.D.J.); and Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (K.D.J.).
Jackson KD; Department of Pharmaceutical Sciences, Lipscomb University College of Pharmacy and Health Sciences, Nashville, Tennessee (J.E.B., V.T., A.A.A., K.J.W., R.D.C., K.D.J.); Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee (R.D.C., K.D.J.); and Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina (K.D.J.) .
Pokaż więcej
Źródło :
Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2019 Nov; Vol. 47 (11), pp. 1257-1269. Date of Electronic Publication: 2019 Sep 06.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms :
Cytochrome P-450 CYP3A/*metabolism
Lapatinib/*pharmacokinetics
Activation, Metabolic ; Adult ; Aged ; Cytochrome P-450 CYP3A/genetics ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Female ; Genotype ; Hepatocytes/metabolism ; Humans ; Liver/metabolism ; Male ; Middle Aged
Czasopismo naukowe
Tytuł :
Involvement of NF-κB in the reversal of CYP3A down-regulation induced by sea buckthorn in BCG-induced rats.
Autorzy :
Liu F; Department of Pharmacology, Institute of Pharmacokinetics and Liver Molecular Pharmacology, Baotou Medical College, Baotou, Inner mongolia, China.
Wang T; Department of Pharmacology, Institute of Pharmacokinetics and Liver Molecular Pharmacology, Baotou Medical College, Baotou, Inner mongolia, China.
Li X; Department of Pharmacology, Institute of Pharmacokinetics and Liver Molecular Pharmacology, Baotou Medical College, Baotou, Inner mongolia, China.
Jia J; Department of Pharmacology, Institute of Pharmacokinetics and Liver Molecular Pharmacology, Baotou Medical College, Baotou, Inner mongolia, China.
Lin Q; Department of Pharmacology, Institute of Pharmacokinetics and Liver Molecular Pharmacology, Baotou Medical College, Baotou, Inner mongolia, China.
Xue Y; Department of Pharmacology, Institute of Pharmacokinetics and Liver Molecular Pharmacology, Baotou Medical College, Baotou, Inner mongolia, China.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Sep 11; Vol. 15 (9), pp. e0238810. Date of Electronic Publication: 2020 Sep 11 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Cytochrome P-450 CYP3A/*genetics
Down-Regulation/*drug effects
Elaeagnaceae/*metabolism
Mycobacterium bovis/*physiology
NF-kappa B/*metabolism
Animals ; Cytochrome P-450 CYP3A/metabolism ; Interleukin-1beta/metabolism ; Liver/drug effects ; Liver/metabolism ; Liver/microbiology ; Liver/pathology ; Male ; Nitric Oxide Synthase Type II/metabolism ; Protein Processing, Post-Translational/drug effects ; Rats ; Rats, Sprague-Dawley ; Transcription, Genetic/drug effects ; Tumor Necrosis Factor-alpha/metabolism
Czasopismo naukowe
Tytuł :
Drug-drug interactions of newly approved small molecule inhibitors for acute myeloid leukemia.
Autorzy :
Megías-Vericat JE; Servicio de Farmacia, Área del Medicamento, Hospital Universitari i Politècnic La Fe. Av. Fernando Abril Martorell, 106, 46026, Valencia, Spain.
Solana-Altabella A; Servicio de Farmacia, Área del Medicamento, Hospital Universitari i Politècnic La Fe. Av. Fernando Abril Martorell, 106, 46026, Valencia, Spain.
Ballesta-López O; Servicio de Farmacia, Área del Medicamento, Hospital Universitari i Politècnic La Fe. Av. Fernando Abril Martorell, 106, 46026, Valencia, Spain.
Martínez-Cuadrón D; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe. Av. Fernando Abril Martorell, 106, 46026, Valencia, Spain.; CIBERONC, Instituto Carlos III, Madrid, Spain.
Montesinos P; Servicio de Hematología y Hemoterapia, Hospital Universitari i Politècnic La Fe. Av. Fernando Abril Martorell, 106, 46026, Valencia, Spain. .; CIBERONC, Instituto Carlos III, Madrid, Spain. .
Pokaż więcej
Źródło :
Annals of hematology [Ann Hematol] 2020 Sep; Vol. 99 (9), pp. 1989-2007. Date of Electronic Publication: 2020 Jul 18.
Typ publikacji :
Journal Article; Review
MeSH Terms :
Drug Approval*
Antineoplastic Agents/*blood
Cytochrome P-450 CYP3A Inhibitors/*blood
Drug Interactions/*physiology
Leukemia, Myeloid, Acute/*blood
Leukemia, Myeloid, Acute/*drug therapy
Antineoplastic Agents/adverse effects ; Benzimidazoles/adverse effects ; Benzimidazoles/blood ; Bridged Bicyclo Compounds, Heterocyclic/adverse effects ; Bridged Bicyclo Compounds, Heterocyclic/blood ; Cytochrome P-450 CYP3A Inhibitors/adverse effects ; Drugs, Investigational/adverse effects ; Drugs, Investigational/metabolism ; Humans ; Long QT Syndrome/blood ; Long QT Syndrome/chemically induced ; Phenylurea Compounds/adverse effects ; Phenylurea Compounds/blood ; Protein Kinase Inhibitors/adverse effects ; Protein Kinase Inhibitors/blood ; Staurosporine/adverse effects ; Staurosporine/analogs & derivatives ; Staurosporine/blood ; Sulfonamides/adverse effects ; Sulfonamides/blood
Czasopismo naukowe
Tytuł :
Burning Pain in the Legs.
Autorzy :
Reghukumar A; Government Medical College, Thiruvananthapuram, Thiruvananthapuram, India .
Benson R; Government Medical College, Thiruvananthapuram, Thiruvananthapuram, India .
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Jul 23; Vol. 383 (4), pp. e18.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Cytochrome P-450 CYP3A Inhibitors/*pharmacology
Ergotamine/*adverse effects
Ergotism/*complications
Ischemia/*diagnostic imaging
Leg/*blood supply
Pain/*chemically induced
Ritonavir/*pharmacology
Adult ; Computed Tomography Angiography ; Cytochrome P-450 CYP3A Inhibitors/adverse effects ; Ergotism/diagnosis ; Female ; HIV Infections/drug therapy ; Humans ; Ischemia/chemically induced ; Leg/diagnostic imaging ; Migraine Disorders/drug therapy ; Ritonavir/adverse effects
Czasopismo naukowe
Tytuł :
Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam.
Autorzy :
Fukuno S; Laboratory of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Osaka Ohtani University , Tondabayashi , Japan.
Nagai K; Laboratory of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Osaka Ohtani University , Tondabayashi , Japan.
Fujiike M; Laboratory of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Osaka Ohtani University , Tondabayashi , Japan.
Sasaki Y; Laboratory of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Osaka Ohtani University , Tondabayashi , Japan.
Konishi H; Laboratory of Clinical Pharmacy and Therapeutics, Faculty of Pharmacy, Osaka Ohtani University , Tondabayashi , Japan.
Pokaż więcej
Źródło :
Xenobiotica; the fate of foreign compounds in biological systems [Xenobiotica] 2019 Dec; Vol. 49 (12), pp. 1470-1477. Date of Electronic Publication: 2019 Mar 05.
Typ publikacji :
Journal Article; Video-Audio Media
MeSH Terms :
Cytochrome P-450 CYP3A/*metabolism
Fluorouracil/*pharmacokinetics
Liver/*metabolism
Midazolam/*pharmacokinetics
Administration, Intravenous ; Animals ; Body Weight/drug effects ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Hydroxylation/drug effects ; Inactivation, Metabolic ; Kinetics ; Liver/drug effects ; Male ; Microsomes, Liver/drug effects ; Microsomes, Liver/metabolism ; Midazolam/administration & dosage ; Midazolam/blood ; Organ Size/drug effects ; Rats, Sprague-Dawley
Czasopismo naukowe
Tytuł :
Neonatal cytochrome P450 CYP3A7: A comprehensive review of its role in development, disease, and xenobiotic metabolism.
Autorzy :
Li H; Sino-German Joint Research Institute Nanchang University, 235 East Nanjing Road, Nanchang, 330047, Jiangxi, PR China.
Lampe JN; University of Colorado, Skaggs School of Pharmacy and Pharmaceutical Sciences, Department of Pharmaceutical Sciences, Mail Stop C238, 12850 E. Montview Blvd., Aurora, CO, 80045, USA. Electronic address: .
Pokaż więcej
Źródło :
Archives of biochemistry and biophysics [Arch Biochem Biophys] 2019 Sep 30; Vol. 673, pp. 108078. Date of Electronic Publication: 2019 Aug 22.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Review
MeSH Terms :
Disease*
Growth and Development*
Cytochrome P-450 CYP3A/*metabolism
Xenobiotics/*metabolism
Base Sequence ; Cytochrome P-450 CYP3A/genetics ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Humans ; Infant, Newborn
Czasopismo naukowe
Tytuł :
Isolation, analysis and in vitro assessment of CYP3A4 inhibition by methylxanthines extracted from Pu-erh and Bancha tea leaves.
Autorzy :
Georgiev KD; Department of Pharmaceutical technologies, Faculty of Pharmacy, Medical University 'Prof. Dr. Paraskev Stoyanov', Varna, 9002, Bulgaria. .
Radeva-Ilieva M; Department of Pharmacology, toxicology and pharmacotherapy, Faculty of Pharmacy, Medical University 'Prof. Dr. Paraskev Stoyanov', Varna, 9002, Bulgaria.
Stoeva S; Department of Pharmacology, toxicology and pharmacotherapy, Faculty of Pharmacy, Medical University 'Prof. Dr. Paraskev Stoyanov', Varna, 9002, Bulgaria.
Zhelev I; Department of Biology, Faculty of Pharmacy, Medical University 'Prof. Dr. Paraskev Stoyanov', Varna, 9002, Bulgaria.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2019 Sep 26; Vol. 9 (1), pp. 13941. Date of Electronic Publication: 2019 Sep 26.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Camellia sinensis/*chemistry
Cytochrome P-450 CYP3A Inhibitors/*chemistry
Tea/*chemistry
Xanthines/*chemistry
Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inhibitors/pharmacology ; Humans ; Xanthines/pharmacology
Czasopismo naukowe
Tytuł :
Effects of CYP3A inhibitors on the pharmacokinetics of quizartinib, a potent and selective FLT3 inhibitor, and its active metabolite.
Autorzy :
Li J; Daiichi Sankyo, Inc, San Diego, CA, USA.
Kankam M; Vince & Associates Clinical Research, Overland Park, KS, USA.
Trone D; Daiichi Sankyo, Inc, San Diego, CA, USA.
Gammon G; Daiichi Sankyo, Inc, San Diego, CA, USA.
Pokaż więcej
Źródło :
British journal of clinical pharmacology [Br J Clin Pharmacol] 2019 Sep; Vol. 85 (9), pp. 2108-2117. Date of Electronic Publication: 2019 Jul 23.
Typ publikacji :
Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Antifungal Agents/*pharmacokinetics
Benzothiazoles/*pharmacokinetics
Cytochrome P-450 CYP3A Inhibitors/*pharmacokinetics
Phenylurea Compounds/*pharmacokinetics
Administration, Oral ; Adolescent ; Adult ; Antifungal Agents/administration & dosage ; Area Under Curve ; Benzothiazoles/administration & dosage ; Cytochrome P-450 CYP3A/metabolism ; Cytochrome P-450 CYP3A Inhibitors/administration & dosage ; Dose-Response Relationship, Drug ; Drug Interactions ; Female ; Fluconazole/administration & dosage ; Fluconazole/pharmacokinetics ; Healthy Volunteers ; Humans ; Invasive Fungal Infections/drug therapy ; Invasive Fungal Infections/immunology ; Ketoconazole/administration & dosage ; Ketoconazole/pharmacokinetics ; Leukemia, Myeloid, Acute/complications ; Leukemia, Myeloid, Acute/drug therapy ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/immunology ; Male ; Middle Aged ; Phenylurea Compounds/administration & dosage ; Young Adult ; fms-Like Tyrosine Kinase 3/antagonists & inhibitors ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies